Home/Filings/4/0000950170-23-033003
4//SEC Filing

Olinger Margaret 4

Accession 0000950170-23-033003

CIK 0001658551other

Filed

Jul 13, 8:00 PM ET

Accepted

Jul 14, 4:20 PM ET

Size

6.7 KB

Accession

0000950170-23-033003

Insider Transaction Report

Form 4
Period: 2023-07-12
Olinger Margaret
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-07-12$0.37/sh+20,000$7,400251,108 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-07-1220,00069,577 total
    Exercise: $0.37Exp: 2029-05-13Common Stock (20,000 underlying)
Footnotes (1)
  • [F1]As of the date of this filing, 67,156 shares subject to the option are vested and exercisable. 2,421 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023.

Documents

1 file

Issuer

Amylyx Pharmaceuticals, Inc.

CIK 0001658551

Entity typeother

Related Parties

1
  • filerCIK 0001898725

Filing Metadata

Form type
4
Filed
Jul 13, 8:00 PM ET
Accepted
Jul 14, 4:20 PM ET
Size
6.7 KB